Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.

We compared the efficacy of immunization with either simian immunodeficiency virus (SIV) Env glycoprotein (Env), Env plus Gag proteins (Gag-Env), or whole inactivated virus (WIV), with or without recombinant live vaccinia vector (VV) priming, in protecting 23 rhesus macaques (six vaccine and two control groups) from challenge with SIVmac251 clone BK28. Vaccination elicited high titers of syncytium-inhibiting and anti-Env (gp120/gp160) antibodies in all vaccinated macaques and anti-Gag (p27) antibodies in groups immunized with WIV or Gag-Env. Only WIV-immunized macaques developed anticell (HuT78) antibodies. After homologous low-dose intravenous virus challenge, we used frequency of virus isolation, provirus burden, and change in antibody titers to define four levels of resistance to SIV infection as follows. (i) No infection ("sterilizing" immunity) was induced only in WIV-immunized animals. (ii) Abortive infection (strong immunity) was defined when virus or provirus were detected early in the postchallenge period but not thereafter and no evidence of virus or provirus was detected in terminal tissues. This response was observed in two animals (one VV-Env and one Gag-Env). (iii) Suppression of infection (incomplete or partial immunity) described a gradient of virus suppression manifested by termination of viremia, declining postchallenge antibody titers, and low levels (composite mean = 9.1 copies per 10(6) cells) of provirus detectable in peripheral blood mononuclear cells or lymphoid tissues at termination (40 weeks postchallenge). This response occurred in the majority (8 of 12) of subunit-vaccinated animals. (iv) Active infection (no immunity) was characterized by persistent virus isolation from blood mononuclear cells, increasing viral antibody titers postchallenge, and high levels (composite mean = 198 copies per 10(6) cells) of provirus in terminal tissues and blood. Active infection developed in all controls and two of three VV-Gag-Env-immunized animals. The results of this study restate the protective effect of inactivated whole virus vaccines produced in heterologous cells but more importantly demonstrate that a gradient of suppression of challenge virus growth, reflecting partial resistance to SIV infection, is induced by subunit vaccination. The latter finding may be pertinent to studies with human immunodeficiency virus vaccines, in which it is plausible that vaccination may elicit significant suppression of virus infection and pathogenicity rather than sterilizing immunity.     

Probing protein-cofactor interactions in the terminal oxidases by second derivative spectroscopy: study of bacterial enzymes with cofactor substitutions and heme A model compounds.

Second derivative absorption spectra are reported for the aa3-cytochrome c oxidase from bovine cardiac mitochondria, the aa3-600 ubiquinol oxidase from Bacillus subtilis, the ba3-cytochrome c oxidase from Thermus thermophilis, and the aco-cytochrome c oxidase from Bacillus YN-2000. Together these enzymes provide a range of cofactor combinations that allow us to unequivocally identify the origin of the 450-nm absorption band of the terminal oxidases as the 6-coordinate low-spin heme, cytochrome a. The spectrum of the aco-cytochrome c oxidase further establishes that the split Soret band of cytochrome a, with features at 443 and 450 nm, is common to all forms of the enzyme containing ferrocytochrome a and does not depend on ligand occupancy at the other heme cofactor as previously suggested. To test the universality of this Soret band splitting for 6-coordinate low-spin heme A systems, we have reconstituted purified heme A with the apo forms of the heme binding proteins, hemopexin, histidine-proline-rich glycoprotein and the H64V/V68H double mutant of human myoglobin. All 3 proteins bound the heme A as a (bis)histidine complex, as judged by optical and resonance Raman spectroscopy. In the ferroheme A forms, none of these proteins displayed evidence of Soret band splitting. Heme A-(bis)imidazole in aqueous detergent solution likewise failed to display Soret band splitting. When the cyanide-inhibited mixed-valence form of the bovine enzyme was partially denatured by chemical or thermal means, the split Soret transition of cytochrome a collapsed into a single band at 443 nm.(ABSTRACT TRUNCATED AT 250 WORDS)     

清栓酶对过氧化脂质含量影响的研究

将５４例冠心病、高血压病、糖尿病及脑梗塞病人,随机分为对照组与清栓酶组。对照组２６例,常规药物治疗,清栓酶组２８例,在常规药物治疗基础上加用蝮蛇清栓酶０．５ｕ,稀释静脉点滴,一日一次,１４天为一疗程。观察到蝮蛇清栓酶能明显升高超氧化物岐化酶活性（Ｐ＜０．０１）,明显降低过氧化脂质的终末代谢产物丙二醛含量（Ｐ＜０．０１）,说明蝮蛇清栓酶能有效减轻自由基损伤。     

HBIG,无环鸟苷,干扰素联合对慢性乙型肝炎抗病毒效应观察

本文报道血清ＨＢＶ复制标志阳性的慢乙肝５４例,随机分为治疗组及对照组各２７例进行ＨＢＩＧ、无环鸟苷、干扰素联合近、远期抗病毒效应观察。治疗组为无环鸟苷第一周按２５～２０ｍｇ／ｋｇ／ｄ计后改１７～１５ｍｇ／ｋｇ／ｄ×５３天,共６０天;人白细胞干扰素１×１０６Ｕ肌注每周３次×４周,后改１．０×１０６Ｕ肌注每周２次×６周,共１０周;ＨＢＩＧ４００Ｕ肌注隔日１次,共１０周,对照组仅给予一般“保肝”药物。其中治疗组１８例,对照组１９例进行治后半年到２年追踪观察,结果近、远期ＨＢｃＡｇ、ＤＮＡＰ、ＨＢＶ－ＤＮＡ阴转率治疗组均高于对照组,其中治疗组近、远期ＨＢｃＡｇ,ＨＢＶ－ＤＮＡ阴转率均达４０％以上,明显高于对照组（Ｐ＜０．０５～０．０１）,治疗组近、远期各有４例及２例ＨＢｓＡｇ阴转,而对照组则无一例阴转,从近、远期综合抗病毒效应观察,治疗组全阴率分别为３３．３％、４４．４％,而对照组分别为３．７９％及０％,Ｐ＜０．０１,治疗组无明显毒副反应。对比单用无环鸟苷,全阴率３１．８％;无环鸟苷加干扰素两药联合全阴率３７．５％,均有所提高,达到４４．４％,值得进一步研究。     

底物膜技术检测精子顶体酶活性的研究

应用底物膜技术检测１３０例正常精液,精子顶体酶活性百分率的正常值下限为５７％。４５９例不孕症病人精液分析,无精症２５例,其余４３４例中７５％精子顶体酶活性正常。实验表明精子密度对数值与顶体酶活性百分率之间有正相关,ｒ＝０．８４（Ｐ＜０．０１）,回归方程为顶体酶活性百分率ｙ＝４８．４３％＋（８．９％）（ｌｏｇ精子计数）。活动精子百分率与顶体酶活性之间有密切正相关,ｒ＝０．９６７,（Ｐ＜０．０１）,顶体酶活性ｙ＝３８．６％＋０、３６ｘ％。前向活跃直线运动精子百分率与顶体酶活性之间也有密切相关．ｒ＝０．９６,（Ｐ＜０．０１）,顶体酶活性ｙ＝３４．２１％＋０．６１ｘ％。     

PCR和生物素探针对HFRSV的检测和分型的探讨

分析比较肾综合征出血热病毒（ＨＦＲＳＶ）７６／１１８株和Ｒ＿（２２）株的核苷酸序列,根据引物设计原则及检测分型的目的,设计并合成了３对引物。１对引物取于两毒株间的高同源区段,作为共同引物和外引物;另两对引物取于两毒株间的低同源区段,分别作为野鼠型引物、家鼠型引物和内引物。建立了ＤＮＡ聚合酶链反应（ＰＣＲ）和ＮｅｓｔＰＣＲ方法,并用ＮｃｓｔＰＣＲ合成了两种型特异的生物素探针。ＰＣＲ检测７６／１１８、Ａ＿９、陈、Ｒ＿２、Ｒ＿２２５个毒株,用外引物时均扩增出１条约３００ｂｐ的条带;用内引物的野鼠型引物时,除Ｒ＿（２２）株之外,其余４株均扩增出１条约７０ｂｐ的条带。斑点杂交试验证实了ＰＣＲ检测分型的准确性。ＮｅｓｔＰＣＲ和生物素探针斑点杂交试验可以测出１－１０ｂｇ的目的ｃＤＮＡ。     

大熊猫消化道消化吸收区段游离面的扫描电镜观察

对大熊猫消化道的消化、吸收区段作扫描电镜观察后表明：（１）胃粘膜上皮细胞排列疏松,细胞表面具微绒毛,（２）十二指肠绒毛呈指状,表面凸凹不乎;绒毛表面具丰富的微绒毛,微绒毛表面粗糙,末端膨大。（３）直肠段具丰富的绒毛结构,表面不平滑,具颗粒状物质,但无微绒毛存在：直肠腺丰富。     

检测特异性抗体分泌细胞(ASCs)的固相酶联免疫斑(ELISPOT)技术的建立

ＥＬＩＳＰＯＴ技术是目前国外评价疫苗免疫原性和免疫应答机理研究中最常使用的方法。本文用自制的ＮＣ膜２４孔板为固相支持物,建立了检测小鼠脾细胞中特异性ＡＳＣｓ的ＥＬＩＳＰＯＴ技术,在检测方法的特异性、结果的稳定性上均取得了满意的效果。并对该方法的某些实验条件进行了摸索。